Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.
Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies.
Kimura
M
M
Department of Urology, Niigata University School of Medicine, Japan.
Tomita
Y
Y
Imai
T
T
Saito
T
T
Katagiri
A
A
Tanikawa
T
T
Takeda
M
M
Takahashi
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000473:pathology*; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000473:pathology*; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D019014:fas Receptor / Q000097:blood*
D019014:fas Receptor